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INTRODUCTION
  Korean National Health Insurance (NHI) was introduced 
in 1963 and became a nationwide health insurance after 
several law reforms in 1988. As a result of nationalization, 
coverage has expanded, and its service level has greatly 
improved since 1998 [1]. However, several diagnostic and 
therapeutic modalities for rare, incurable diseases such as 
malignant hematologic diseases are excluded from the re-
imbursement criteria, and this often complicates physicians’ 
decision making in terms of evidence-based guidelines. The 
diagnosis and treatment of hematologic diseases have been 
rapidly advancing in recent years. However, NHI policy 
limitations hinder the addition of these advances to standard 
practice guidelines. Furthermore, the system’s current prin-
ciple of basic equal sharing regardless of disease severity 
will inevitably lead to a budget deficit. In this article, we 
aim to illuminate the insurance problems that arise in the 
treatment of hematologic diseases under the current NHI 
and propose solutions to these problems.
INSURANCE POLICY FOR NEW HIGH-PRICED DRUGS
The percentage of NHI-reimbursed health and medical fees 
that is used on pharmaceutical expenditure has been increas-
ing since 2000 (Fig. 1), and expenditure has increased by 
14% since 2001 [2]. Moreover, the development of new 
drugs, such as molecular-targeted agents, is expected to fur-
ther increase expenditure. Currently, a “selective registra-
tion system” based on the cost-efficiency of new drugs is 
used to determine insurance reimbursement. Therefore, a 
product with poor cost-effectiveness will be designated as 
a product that will not be reimbursed by health insurance. 
This policy is more strictly applied to new high-priced drugs. 
Although this system has the advantage of reducing the 
proposed price of new drugs to an appropriate level, it has 
the disadvantage of delaying their introduction into clinical 
practice. It is essential to maintain reasonable control of 
drug costs to both adequately provide high-quality medicine 
that is critical for disease treatment and stabilize the in-
surance budget. Therefore, when estimating the price of 
new drugs, the establishment of a pharmaceutical policy 
based on Korea’s purchasing power is crucial to secure price 
equality among nations. An expanded drug cost re-evalua-
t i o n  p o l i c y  t o  a d j u s t  t h e  p r i c e  o f  a  n e w  d r u g  a c c o r d i n g  
to its usage is also needed. In addition, once a drug patent 
has expired, the price should decrease, and a continuous 
control system for registered reimbursement drugs should 
be implemented to prevent unnecessary budget spending. 
INSURANCE POLICY FOR PATIENTS WITH RARE, 
INCURABLE HEMATOLOGIC DISEASES 
  Although NHI generally does not cover rare, incurable 
diseases because of their rarity, there are approximately Korean J Hematol 2011;46:6-8.
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Fig. 1. Increase of drug cost.
320,000 patients suffering from 132 rare diseases in Korea. 
Many of these patients suffer from rare hematologic diseases 
such as hemophilia. The government is trying to enroll 
low-income individuals into the Medical Aid Program 
(MAP) to increase support for those with rare, incurable 
diseases and ease the burden for NHI member patients by 
reducing medical payments to 10%. However, these system-
atic supports are limited to NHI reimbursement services, 
since the patient pays fees for non-reimbursement services. 
Because of their uniqueness, the study and treatment of 
rare, incurable diseases need support from the entire nation. 
We need to better understand these diseases and the eco-
nomic burden they place on a patient. Society should show 
an interest in these patients and continuously support them 
with donations and sponsorships.
INSURANCE POLICY FOR GERIATRIC PATIENTS WITH 
HEMATOLOGIC DISEASES
  According to the 2008 Geriatric Population Investigation 
Report published by the Korean National Statistics Office, 
10.3% (5 million) of the population was 65 years of age 
or older (www.kosis.kr). Since most malignant hematologic 
diseases occur at an older age, as the elderly population 
increases, a sharp increase in both the number of patients 
with hematologic diseases and medical spending on their 
treatment is expected [3]. According to September 2008 
data from the Health Insurance Review and Assessment 
Service (HIRAS; 2007 Health Insurance Statistics Annual 
Report), in 2007, 4.4 million (9.2%) NHI members were 
aged over 65 years, whereas 486,000 (26.2%) medical re-
imbursement recipients were age 65 years or older. NHI 
reimbursements for geriatric medical fees was 9.8 trillion 
in 2007, which is a 22.8% increase from 2006, and this 
comprised 28.2% of all medical expenses, up from 25.9% 
in 2006 [4]. Therefore, the government needs to prepare 
for these ever-increasing medical fees by securing sufficient 
funds to cover them. Efforts should be made by medical 
professionals to evaluate the accompanying diseases and 
prognosis of geriatric patients in order to administer 
high-priced drugs to only those who could benefit from 
them. Furthermore, clinical studies should be implemented 
to determine the proper doses and methods of administration 
for drugs in the geriatric population.
INSURANCE POLICY FOR PEDIATRIC PATIENTS WITH 
HEMATOLOGIC DISEASES
  Nowadays, insurance reimbursement seems to be moving 
in the direction of rational decision making partly based 
on evidence-based medicine. However, gathering enough 
data for evidence-based decision making in the treatment 
of pediatric hematologic diseases is a long and difficult process, 
since every year only 1,200 children under 15 years of 
age become pediatric cancer patients in Korea. From the 
point of view of pharmaceutical companies, the number 
of pediatric patients is relatively small compared to that 
of adult patients; thus, studies on pediatric subjects are diffi-
cult because pediatric patients are excluded from clinical 
research in most pharmaceutical companies. Therefore, 
there are relative disadvantages in terms of insurance re-
imbursement for pediatric hematologic patients. Recently, 
financial support plans have been drawn up for the treatment 
of rare pediatric diseases, and in the National Assembly, 
a bill was proposed that called for full financial support 
of medical fees for the treatment of pediatric neoplasms 
and rare diseases. However, even with this support, the 
medical fees paid by the patient’s family will increase as 
the number of non-reimbursement drugs increases. This 
could lead physicians to either illegally administer drugs 
against a patient’s will or to stop treatment. To ensure that 
pediatric patients with hematologic diseases grow into 
healthy members of our society, the NHI needs a new policy 
that expands reimbursement for drugs needed to treat pedia-
tric patients with these diseases.
PRIVATE HEALTH INSURANCE POLICY FOR PATIENTS 
WITH HEMATOLOGIC DISEASES
  According to the “Report of Korea Health Panel Survey 
2008” by the Korea Institute for Health and Social Affairs 
(KIHASA) and the NHI Corporation, 76.1% of 7,866 house-
holds surveyed (24,616 people) had private health insurance. 
The number of signed contracts per household (mean, 3.13 
persons per household) was 0.74 for single-person house-
holds, 1.58 for 2-person households, 3.32 for 3-person house-
holds, and 4.99 for 4-person households [5]. Despite the 
fact that Korean NHI is more accessible than that of other 
Organisation for Economic Co-operation and Development 
(OECD) nations and that the benefits from Korean NHI 
are increasing, 76.1% still chose to have private insurance. 
The reason for this could be insufficient support from public 
health insurance against financial losses due to diseases. Korean J Hematol 2011;46:6-8.
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However, it is also important to note that support for in-
curable diseases, including hematologic neoplasms, is being 
increased and that the high-cost treatments currently sup-
ported by private health insurance might no longer be stand-
ard treatments. Therefore, future financial support based 
on current standard guidelines could inevitably cause a gap 
between the effectiveness of private health insurance and 
an individual’s expectations. To curtail the role of private 
health insurance, the current social welfare system needs 
to be supplemented financially, and public insurance must 
play the major role in reimbursement, whereas private 
health insurance should play a supplemental role and pay 
for any fees not covered by public insurance.
INSURANCE POLICY FOR LABORATORY TESTS
  With the advancement in molecular and immunological 
diagnostic techniques for hematologic diseases, particularly 
malignant hematologic diseases, these techniques are be-
coming more routinely used. In fact, the operation of a 
cellular genetics laboratory within a clinical laboratory is 
now mandatory for the WHO classification, and the use 
of flexible and creative immunophenotyping techniques for 
the precise diagnosis of equivocal cases is increasing. 
Reimbursement policy should be flexible to allow for the 
determination of complex and overlapping immunopheno-
types of various cancers. This flexibility could be achieved 
through expanded reimbursement and the rationalization 
of medical fees. Although the quality, sensitivity, and specif-
icity of clonality analysis of immunoreceptor gene re-
arrangements in lymphoma and leukemia have greatly im-
proved since the GeneScan method was introduced, re-
imbursement for diagnosis remains at the same level as 
when the Southern blot test was the methodology of choice. 
Because of this cost restriction, there is very limited use 
of newly developed tests in clinical practice. However, as 
future research on the detection of minimal residual disease 
in lymphoblastic leukemia/lymphoma and the analysis of 
immunoreceptors extends the understanding of the im-
portance of newly developed methodology, an improved 
reimbursement policy is expected. Expanded discussions on 
the fees for rapid subtype analysis of leukemia and fluo-
rescent in situ hybridization for cytogenetic analysis of lym-
phoma or myeloma cells are needed. Furthermore, when 
deciding the appropriate laboratory test fees, various factors 
such as establishing, maintaining, and analyzing test results 
must be considered.
THE REALITY AND PROSPECTS OF AN ARBITRARY 
NON-REIMBURSEMENT POLICY
  On November 11, 2010, the Seoul High Court dismissed 
charges brought forward by the Korean Ministry of Health 
and Welfare and the NHI Corporation against Youido St. 
Mary's Hospital, The Catholic University of Korea. The judg-
es in the decision emphasized that “If cases of additional 
charges to the patient under agreement with the patient 
are restricted, this would be seen as a violation of the pa-
tient’s right to receive treatment, right to his own will, 
and the freedom of professional practice by physicians.” 
In the current NHI system, only publicly notified cases 
are considered for reimbursement or non-reimbursement, 
and insurance is only applied for patients included in these 
cases. This limits rapid adaptation to advanced therapeutic 
modalities. Furthermore, patients’ expectations for the latest 
treatment often causes controversy with physicians who 
are stuck in the non-reimbursement system, and this can 
seriously damage the trust between physicians and patients. 
The government should realize that problems with non-re-
imbursement cause irrational issues and should put forth 
the effort to rapidly resolve these problems. 
CONCLUSION
  The benefit of NHI for patients is that it affords high-qual-
ity medical services without a heavy financial burden. 
However, a breakdown of the medical referral system, which 
occurs because patients are free to use the medical institution 
of their choice, leads to increased medical costs and limits 
preservation of the current reimbursement system. The gov-
ernment is implementing various measures to lower costs 
to overcome such obstacles; however, as was demonstrated 
in the non-reimbursement charge case involving Youido 
St. Mary’s Hospital, there are limits to what such measures 
can do. To provide effective reimbursement benefits with 
limited resources, the policy of “mere kindness” should be 
discouraged, and support for the treatment of diseases re-
quiring high-level and high-cost treatments should be 
expanded. As in developed countries, medical experts must 
have a pivotal role in determining reimbursement for these 
diseases. To promote better health for the people, efforts 
such as appealing to professional opinion should be en-
couraged. In summary, we believe that the NHI system 
should be improved to provide increased benefits to patients 
with severe diseases that currently result in them incurring 
huge financial burdens because of non-reimbursement.
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